• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Helper
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees for your businessNEW
    Legal
    Terms of usePrivacy policyCookie policy

    Courtney Phillips sold $2,645 worth of shares (7,061 units at $0.37), decreasing direct ownership by 12% to 50,431 units (SEC Form 4)

    4/3/24 9:33:32 PM ET
    $BCEL
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $BCEL alert in real time by email
    SEC FORM 4 SEC Form 4
    FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

    Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
    or Section 30(h) of the Investment Company Act of 1940
    OMB APPROVAL
    OMB Number: 3235-0287
    Estimated average burden
    hours per response: 0.5
      
    Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
      
    Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
    1. Name and Address of Reporting Person*
    Courtney Phillips

    (Last) (First) (Middle)
    C/O ATRECA, INC., 835 INDUSTRIAL RD.
    SUITE 400

    (Street)
    SAN CARLOS CA 94070

    (City) (State) (Zip)
    2. Issuer Name and Ticker or Trading Symbol
    Atreca, Inc. [ BCEL ]
    5. Relationship of Reporting Person(s) to Issuer
    (Check all applicable)
    Director 10% Owner
    X Officer (give title below) Other (specify below)
    GENERAL COUNSEL & SECRETARY
    3. Date of Earliest Transaction (Month/Day/Year)
    09/01/2023
    4. If Amendment, Date of Original Filed (Month/Day/Year)
    6. Individual or Joint/Group Filing (Check Applicable Line)
    X Form filed by One Reporting Person
    Form filed by More than One Reporting Person
    Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
    1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V Amount (A) or (D) Price
    Class A Common Stock 09/01/2023 S 7,061(1) D $0.3746 50,431 D
    Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
    (e.g., puts, calls, warrants, options, convertible securities)
    1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
    Explanation of Responses:
    1. Represents the number of shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. The sale occurred automatically to satisfy the tax withholding obligations to be funded by a "sell to cover" and does not represent a discretionary trade by the Reporting Person.
    /s/ Courtney J. Phillips 04/03/2024
    ** Signature of Reporting Person Date
    Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
    * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
    ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
    Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
    Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
    Get the next $BCEL alert in real time by email

    Crush Q3 2025 with the Best AI Executive Assistant

    Stay ahead of the competition with Tailforce.ai - your AI-powered business intelligence partner.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Tailforce.ai

    Recent Analyst Ratings for
    $BCEL

    DatePrice TargetRatingAnalyst
    3/4/2022$17.00 → $14.00Buy
    Stifel
    More analyst ratings

    $BCEL
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Stifel reiterated coverage on Atreca with a new price target

      Stifel reiterated coverage of Atreca with a rating of Buy and set a new price target of $14.00 from $17.00 previously

      3/4/22 7:37:56 AM ET
      $BCEL
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Robert W. Baird resumed coverage on Atreca with a new price target

      Robert W. Baird resumed coverage of Atreca with a rating of Outperform and set a new price target of $27.00 from $30.00 previously

      6/4/21 7:01:08 AM ET
      $BCEL
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Jefferies initiated coverage on Atreca with a new price target

      Jefferies initiated coverage of Atreca with a rating of Buy and set a new price target of $30.00

      2/8/21 5:57:56 AM ET
      $BCEL
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $BCEL
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Orwin John A bought $0 worth of Series A Junior Preferred Stock (1 units at $0.01) (SEC Form 4)

      4 - Atreca, Inc. (0001532346) (Issuer)

      4/17/24 7:36:28 PM ET
      $BCEL
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Serafini Tito sold $1,455 worth of shares (20,788 units at $0.07), decreasing direct ownership by 32% to 43,636 units (SEC Form 4)

      4 - Atreca, Inc. (0001532346) (Issuer)

      4/3/24 9:50:22 PM ET
      $BCEL
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Orwin John A sold $8,597 worth of shares (22,951 units at $0.37), decreasing direct ownership by 23% to 77,541 units (SEC Form 4)

      4 - Atreca, Inc. (0001532346) (Issuer)

      4/3/24 9:37:17 PM ET
      $BCEL
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $BCEL
    SEC Filings

    See more
    • SEC Form DEFM14A filed by Atreca Inc.

      DEFM14A - Atreca, Inc. (0001532346) (Filer)

      4/22/24 9:21:58 AM ET
      $BCEL
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form PREM14A filed by Atreca Inc.

      PREM14A - Atreca, Inc. (0001532346) (Filer)

      4/11/24 4:52:06 PM ET
      $BCEL
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 15-12G filed by Atreca Inc.

      15-12G - Atreca, Inc. (0001532346) (Filer)

      4/1/24 4:31:35 PM ET
      $BCEL
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $BCEL
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Orwin John A bought $0 worth of Series A Junior Preferred Stock (1 units at $0.01) (SEC Form 4)

      4 - Atreca, Inc. (0001532346) (Issuer)

      4/17/24 7:36:28 PM ET
      $BCEL
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $BCEL
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Immunome to Acquire Antibody-Related Assets and Materials from Atreca

      Immunome, Inc. (NASDAQ:IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, today announced that it entered into a definitive asset purchase agreement with Atreca, Inc. (NASDAQ:BCEL) to acquire a collection of antibody-related assets and materials. "We believe that novel and underexplored targets will drive the next generation of transformative ADCs. These antibody-related assets will expand our toolbox, complementing our existing programs as we advance our mission of developing innovative treatments for cancer patients," stated Clay B. Siegall, Ph.D., Chairman and Chief Executive Officer of Immunome. Under the terms of the ass

      12/26/23 8:30:00 AM ET
      $BCEL
      $IMNM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Atreca Announces Asset Purchase Agreement for Sale of Antibody-Related Assets and Materials to Immunome

      CAMPBELL, Calif., Dec. 26, 2023 (GLOBE NEWSWIRE) -- Atreca, Inc. ("Atreca") (NASDAQ:BCEL), a biotechnology company focused on developing novel therapeutics generated through a unique discovery platform based on interrogation of the active human immune response, today announced that it entered into a definitive asset purchase agreement with Immunome, Inc. (NASDAQ:IMNM) to sell a collection of antibody-related assets and materials. Under the terms of the agreement, Immunome would pay Atreca up to $12.5 million, consisting of a $5.5 million upfront payment and up to $7.0 million in clinical development milestones. "We are pleased to announce this asset purchase agreement with Immunome, a com

      12/26/23 8:30:00 AM ET
      $BCEL
      $IMNM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Atreca Reports Third Quarter 2023 Financial Results and Announces Further Reorganization to Support Exploration of Strategic Alternatives

      SAN CARLOS, Calif., Nov. 14, 2023 (GLOBE NEWSWIRE) -- Atreca, Inc. (Atreca) (NASDAQ:BCEL), a clinical-stage biotechnology company focused on developing novel therapeutics generated through a unique discovery platform based on interrogation of the active human immune response, today reported financial results for the third quarter ended September 30, 2023, and announced that the Company is implementing a further reduction in its workforce of approximately 40% while maintaining the necessary support to continue exploring potential strategic transactions and business alternatives. "Since our founding, Atreca has leveraged a unique discovery platform to identify numerous antibodies binding no

      11/14/23 4:30:08 PM ET
      $BCEL
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $BCEL
    Leadership Updates

    Live Leadership Updates

    See more
    • Atreca Appoints Philippe Bishop, MD as Chief Medical Officer

      SAN CARLOS, Calif., Jan. 09, 2023 (GLOBE NEWSWIRE) -- Atreca, Inc. (Atreca) (NASDAQ:BCEL), a clinical-stage biotechnology company focused on developing novel therapeutics generated through a unique discovery platform based on interrogation of the active human immune response, today announced the appointment of Philippe Bishop, MD, as Chief Medical Officer (CMO), effective immediately. "Dr. Bishop is a tremendous addition to the Atreca team at an important time in the clinical development of ATRC-101. As an accomplished executive and medical oncologist with extensive experience in cancer drug development, his leadership and expertise will be invaluable as we continue to advance ATRC-101, a

      1/9/23 8:30:54 AM ET
      $BCEL
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Cellino Announces Appointment of Abhijit Kulkarni, Ph.D. as Chief Operating Officer and Paulette Dillon as Chief Business Officer

      - Industry Veterans Expand Company's Business and Operations Functions Cellino Biotech, Inc., an autonomous cell therapy technology platform company, today announced the expansion of its executive leadership team with the appointments of Abhijit (Abhi) Kulkarni, Ph.D. as Chief Operating Officer and Paulette Dillon as Senior Vice President (SVP) and Chief Business Officer. Together, these leaders will support the company's growth and further enhance its ability to build an integrated technology platform for the development and scaling of regenerative medicines. "We are delighted to welcome Abhi and Paulette, who bring invaluable expertise in advanced technology development and business to

      6/27/22 8:00:00 AM ET
      $BCEL
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Atreca Appoints Stephen Gould, Ph.D. as Chief Scientific Officer

      SAN CARLOS, Calif., June 16, 2022 (GLOBE NEWSWIRE) -- Atreca, Inc. (Atreca) (NASDAQ:BCEL), a clinical-stage biotechnology company focused on developing novel therapeutics generated through a unique discovery platform based on interrogation of the active human immune response, today announced the appointment of Stephen Gould, Ph.D., as Chief Scientific Officer. "Stephen is an exceptional scientific leader with particular experience in the development of weaponized antibody-based therapeutics, and we are excited to welcome him to the Atreca team," said John Orwin, Chief Executive Officer of Atreca. "Our discovery platform has proven to be highly productive in generating promising tumor-sele

      6/16/22 4:05:22 PM ET
      $BCEL
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $BCEL
    Financials

    Live finance-specific insights

    See more
    • Atreca Reports Fourth Quarter and Full-Year 2022 Financial Results and ATRC-101 Data Update

      ATRC-101 continues to be well tolerated in ongoing Phase 1b trial; clinical activity observed in multiple tumor types; longer progression free survival observed in patients with high target expression Phase 2 go/no-go decisions for ATRC-101 expected by end-of-year APN-497444 and APN-346958 programs advancing with nomination of clinical candidates expected in 2023 Conference call and webcast with accompanying slides scheduled for today at 4:30 p.m. EDT SAN CARLOS, Calif., March 29, 2023 (GLOBE NEWSWIRE) -- Atreca, Inc. (Atreca) (NASDAQ:BCEL), a clinical-stage biotechnology company focused on developing novel therapeutics generated through a unique discovery platform based on interrogati

      3/29/23 4:05:12 PM ET
      $BCEL
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Atreca to Host Fourth Quarter and Year End 2022 Conference Call and Webcast on March 29, 2023

      SAN CARLOS, Calif., March 23, 2023 (GLOBE NEWSWIRE) -- Atreca, Inc. (Atreca) (NASDAQ:BCEL), a clinical-stage biotechnology company focused on developing novel therapeutics generated through a unique discovery platform based on interrogation of the active human immune response, today announced that it will host a conference call and webcast on Wednesday, March 29, 2023, at 4:30 p.m. EDT to report financial results and provide an update on its discovery platform and pipeline, including updated data from the ongoing Phase 1b trial of ATRC-101. To access the conference call by telephone, please use this link to register and receive the dial-in numbers and unique PIN to access the call. To acc

      3/23/23 5:00:36 PM ET
      $BCEL
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Atreca Announces Expansion of Preclinical Pipeline

      Atreca Announces Licensing Agreement with Zymeworks Atreca Declares EphA2-Targeting ADC (ATRC-301) as Clinical Candidate Virtual R&D Day scheduled for today at 4:15 p.m. EDT SAN CARLOS, Calif., April 05, 2022 (GLOBE NEWSWIRE) -- Atreca, Inc. (Atreca) (NASDAQ:BCEL), a clinical-stage biotechnology company focused on developing novel therapeutics generated through a unique discovery platform based on interrogation of the active human immune response, today announced a licensing agreement with Zymeworks Inc. (Zymeworks) (NYSE:ZYME) to utilize their ZymeLink™ technology to develop novel antibody-drug conjugates (ADCs) and declared ATRC-301, an ADC targeting a novel epitope on EphA2, as the C

      4/5/22 4:01:00 PM ET
      $BCEL
      $ZYME
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $BCEL
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G filed by Atreca Inc.

      SC 13G - Atreca, Inc. (0001532346) (Subject)

      1/10/24 4:52:48 PM ET
      $BCEL
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by Atreca Inc. (Amendment)

      SC 13G/A - Atreca, Inc. (0001532346) (Subject)

      12/7/22 10:24:32 AM ET
      $BCEL
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by Atreca Inc. (Amendment)

      SC 13G/A - Atreca, Inc. (0001532346) (Subject)

      2/14/22 4:47:03 PM ET
      $BCEL
      Biotechnology: Pharmaceutical Preparations
      Health Care